ReportWire

Tag: johnson & johnson

  • Allianz SE Decreases Stake in Johnson & Johnson $JNJ

    [ad_1]

    Allianz SE cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,221 shares of the company’s stock after selling 8,085 shares during the period. Allianz SE’s holdings in Johnson & Johnson were worth $20,350,000 as of its most recent filing with the Securities and Exchange Commission.

    Several other institutional investors have also modified their holdings of the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $35,000. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the first quarter worth approximately $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson in the first quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. acquired a new stake in Johnson & Johnson during the first quarter worth approximately $65,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

    Johnson & Johnson Stock Performance

    Shares of JNJ opened at $194.52 on Thursday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $195.55. The stock has a market capitalization of $468.65 billion, a P/E ratio of 18.78, a P/E/G ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company’s fifty day moving average is $185.13 and its two-hundred day moving average is $169.48.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

    Johnson & Johnson Announces Dividend

    The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

    Wall Street Analysts Forecast Growth

    JNJ has been the topic of a number of recent analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a research report on Friday, October 10th. Argus set a $210.00 price objective on Johnson & Johnson in a report on Wednesday, October 15th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Finally, Stifel Nicolaus boosted their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $199.05.

    Check Out Our Latest Stock Report on Johnson & Johnson

    Insider Activity

    In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

    Johnson & Johnson Company Profile

    (Free Report)

    Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

    Featured Articles

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal

    [ad_1]

    Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

    Shareholders of Kimberly-Clark will own about 54% of the combined company. Kenvue shareholders will own about 46% in what is one of the largest corporate takeovers this year. The deal must still be approved by the shareholders of both companies.

    The combined company will have a huge stable of household brands under one roof, putting Kenvue’s Listerine mouthwash and Band-Aid side-by-side with Kimberly-Clark’s Cottonelle toilet paper, Huggies and Kleenex tissues. It will also generate about $32 billion in annual revenue.

    Kenvue has spent a relatively brief period as an independent company, having been spun off by Johnson & Johnson two years ago. J&J first announced in late 2021 that it was splitting its slow-growth consumer health division from the pharmaceutical and medical device divisions.

    Kenvue has since been targeted by activist investors unhappy about the trajectory of the company and Wall Street appeared to anticipate some heavy lifting ahead for Kimberly-Clark.

    Kenvue’s stock jumped 12% Monday afternoon, while shares of Kimberly-Clark, based outside of Dallas, slumped by nearly 15%.

    Kenvue shares have shed nearly 50% of their value since approaching $28 in the spring of 2023. Morningstar analyst Keonhee Kim said Kenvue’s volatile journey as a public company may have been driven in part by poor execution and a lack of experience operating as a stand-alone business.

    He said the leadership of a more-established consumer products company like Kimberly-Clark could help unlock some of Kenvue’s value.

    He also noted that Kenvue brands include Neutrogena, Benadryl and other names that have been in store consumer health aisles for decades. Kim said he thinks Kimberly-Clark may have seen upside in adding those products.

    “I think that may have made the deal a lot more attractive … especially after the past couple of months of Kenvue’s stock price decline,” he said.

    Kenvue and Tylenol have been thrust into the national spotlight this year as President Donald Trump and Health Secretary Robert F. Kennedy Jr. promoted unproven and in some cases discredited ties between Tylenol, vaccines and the complex brain disorder autism.

    Trump then urged pregnant women against using the medicine. That went beyond Food and Drug Administration advice that doctors “should consider minimizing” the painkiller acetaminophen’s use in pregnancy — amid inconclusive evidence about whether too much could be linked to autism.

    Kennedy reiterated the FDA guidance during a press conference last week. He said that there isn’t sufficient evidence to link the drug to autism.

    “We have asked physicians to minimize the use to when it’s absolutely necessary,” he said.

    Kenvue has continued to push back on the Trump administration’s public statements about Tylenol and acetaminophen, the active ingredient it contains.

    “We strongly disagree with allegations that it does and are deeply concerned about the health risks and confusion this poses for expecting mothers and parents,” Kenvue said in a statement on its website.

    The merger could face other hurdles. Citi Investment Research analyst Filippo Falorni said he is concerned about the deal’s size given the recent history in the sector, particularly given the challenges faced by Kenvue.

    In July, Kenvue announced that CEO Thibaut Mongon was leaving in the midst of a strategic review, with the company under mounting pressure from activist investors unhappy about growth. Critics say Kenvue has relied too much on its legacy brands and failed to innovate.

    Industry analysts also point out the poor track record for mergers involving consumer packaged goods companies. In September, Kraft Heinz said it would break up its decade-old merger. Its net revenue has fallen every year since 2020.

    Kimberly-Clark and Kenvue, like Kraft Heinz, are facing increasing competition from cheaper store brands. In 2024, 51% of toilet paper and other household paper products sold in the U.S were store brands, according to Circana, a market research company, while store brands held a 24% share of sales of health products, including medications and vitamins.

    On Monday, a bottle of 100 extra-strength Tylenol caplets cost $10.97 on Walmart’s website. A bottle of 100 extra-strength acetaminophen caplets from Walmart’s Equate brand cost $1.98.

    Inflation drove some of that buyer behavior, Circana said. Shoppers are also shifting their purchases to stores with more private-label brands, like Aldi and Costco. And stores are improving their offerings and adding more of them; last year, Walmart and Target both launched new store brands to complement their existing ones.

    Still, both Kimberly-Clark and Kenvue make name-brand products in segments where consumers are less likely to shift to store brands, including hair care, skin care, feminine products and mouth care, according to Circana. Kenvue owns brands like Aveeno and Neutrogena, for example, while Kimberly-Clark makes Kotex and Depend.

    Kimberly-Clark Chairman and CEO Mike Hsu will be chairman and CEO of the combined company. Three members of the Kenvue’s board will join Kimberly-Clark’s board at closing. The combined company will keep Kimberly-Clark’s headquarters in Irving, Texas, but there will be significant operations around Kenvue facilities and locations as well.

    The deal is expected to close in the second half of next year. It still needs approval from shareholders of both both companies.

    Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. That amounts to $21.01 per share, based on the closing price of Kimberly-Clark shares on Friday.

    Kimberly-Clark and Kenvue said that they identified about $1.9 billion in cost savings that are expected in the first three years after the transaction’s closing.

    ___

    AP Health Writer Tom Murphy contributed to this report.

    [ad_2]

    Source link

  • Texas attorney general sues Tylenol makers, claiming links to autism

    [ad_1]

    (CNN) — Texas Attorney General Ken Paxton has filed a lawsuit against the companies Johnson & Johnson and Kenvue, claiming that they “deceptively” marketed Tylenol to pregnant mothers and that the medication is tied to an increased risk of autism. Kenvue said in a statement that the medication is safe and the company will “vigorously defend” against the claims.

    The lawsuit, dated Monday and filed in the District Court of Panola County, Texas, comes about a month after President Donald Trump publicly claimed that the use of Tylenol during pregnancy can be associated with an increased risk of autism in the child, despite decades of evidence that the medication is safe.

    “Big Pharma betrayed America by profiting off of pain and pushing pills regardless of the risks. These corporations lied for decades, knowingly endangering millions to line their pockets,” Paxton, the state’s Republican attorney general, who is also running for US Senate, said in a news release Tuesday. “By holding Big Pharma accountable for poisoning our people, we will help Make America Healthy Again.”

    The lawsuit claims that Johnson & Johnson and Kenvue violated the Texas Deceptive Trade Practices-Consumer Protection Act because they knew that acetaminophen, the active ingredient in Tylenol, “is dangerous to unborn children and young children” and “they hid this danger and deceptively marketed Tylenol as the only safe painkiller for pregnant women,” according to the lawsuit.

    The state’s lawsuit has requested a jury trial and, in part, calls for the companies to “destroy any marketing or advertising materials in their possession that represent, directly or indirectly, that Tylenol is safe for pregnant women and children.” The lawsuit also calls for the companies to pay civil penalties to the state in the amount of $10,000 per violation.

    “Nothing is more important to us than the health and safety of the people who use our products. We are deeply concerned by the perpetuation of misinformation on the safety of acetaminophen and the potential impact that could have on the health of American women and children,” Kenvue said in an emailed statement Tuesday.

    “We will vigorously defend ourselves against these claims and respond per the legal process. We stand firmly with the global medical community that acknowledges the safety of acetaminophen and believe we will continue to be successful in litigation as these claims lack legal merit and scientific support,” the statement said in part. “We also encourage expecting mothers to speak to their health professional before taking any over-the-counter medication, including acetaminophen, as indicated on our product label for Tylenol®.”

    In a statement, a Johnson & Johnson company spokesperson said it “divested its consumer health business years ago, and all rights and liabilities associated with the sale of its over-the-counter products, including Tylenol (acetaminophen), are owned by Kenvue.”

    Texas Attorney General Ken Paxton filed a lawsuit that says makers of Tylenol “deceptively marketed” the medication as the “only safe painkiller for pregnant women.” Credit: Mandel Ngan/AFP / Getty Images via CNN Newsource

    Experts have said there are multiple causes of autism, and the science showing a connection between autism and Tylenol is not settled.

    “Suggestions that acetaminophen use in pregnancy causes autism are not only highly concerning to clinicians but also irresponsible when considering the harmful and confusing message they send to pregnant patients, including those who may need to rely on this beneficial medicine during pregnancy,” Dr. Steven J. Fleischman, president of the American College of Obstetricians and Gynecologists, said in a statement in September.

    “Acetaminophen is one of the few options available to pregnant patients to treat pain and fever, which can be harmful to pregnant people when left untreated. Maternal fever, headaches as an early sign of preeclampsia, and pain are all managed with the therapeutic use of acetaminophen, making acetaminophen essential to the people who need it,” he said. “The conditions people use acetaminophen to treat during pregnancy are far more dangerous than any theoretical risks and can create severe morbidity and mortality for the pregnant person and the fetus.”

    [ad_2]

    Jacqueline Howard and CNN

    Source link

  • J&J Announces Second Major Spinoff, Plans to Separate Orthopedics Division

    [ad_1]

    Johnson & Johnson (NYSE:JNJ) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now.

    J&J Announces Second Major Spinoff, Plans to Separate Orthopedics Division

    Johnson & Johnson (NYSE:JNJ) is an American multinational pharmaceutical, biotech, and medical technologies company.

    On Oc‍tober 14,​ the company⁠ announced that it will spin​ off i‌ts orthopedics division into a​ sepa‌rate company within the next 18 to 24 months. This move marks its second major spin-off in two ye‍a⁠rs as the healthcare giant continues​ to shift focus toward higher-grow⁠th se‌gmen‍ts.

    Johnson & Johnson (NYSE:JNJ) also shared an optimistic outlook​ for 2026, supported by new drug launches and a‌n expan⁠ding medical devices portfolio. J‍&J expe⁠c​ts revenue growth to surpass 5% next year, a‍bove‍ analysts’ forecasts of 4.6%,‌ and project‍s adjuste‌d ear‌nings to exceed​ Wall​ Street’s es‌timat⁠e o‌f‍ $11.39 per share by up to 5 cents.

    The orthopedics business, which pro⁠duce⁠s im‌plants for hips, knees, and shoulders⁠ as well as surgical‍ instruments and relat⁠ed devices, ge‌nerated about $9.2 billion in re⁠venue la‍st year, roughly 10% o‌f the com‌pany’s‌ t⁠ota⁠l sales. After the se⁠para⁠tion, the new company will be called DePuy Synthes and l‍ed‌ by i‍ndu⁠stry veteran Namal Nawana.

    In 2023, Johnson & Johnson (NYSE:JNJ) l‌aunched a two-year restructuring plan for its or‌tho​pedics unit, inc‍l‍uding market exits and prod‌uct‍ discontinuations, shortly after‍ spinning off its $‍15‌ billion consumer health​ bus‌iness​ into Kenvue.

    Desp‍ite these maj⁠or transformat​ions, Johnson & Johnson (NYSE:JNJ) h‍as conti‌nued to‍ uphold its stro⁠ng dividend tradition, having raised its payouts for 63 consecutive years. The company offers a quarterly dividend of $1.30 per share and has a dividend yield of 2.74%, as of October 14.

    While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 11 Low PE High Dividend Stocks to Buy According to Analysts and 12 Reliable Dividend Stocks for Maximum Income.

    Disclosure: None.

    [ad_2]

    Source link

  • Barclays Maintains a Hold Rating on Johnson & Johnson (JNJ) With a $176 PT

    [ad_1]

    Johnson & Johnson (NYSE:JNJ) is one of the best medical stocks to buy now. In a report released on September 30, Matt Miksic from Barclays maintained a Hold rating on Johnson & Johnson (NYSE:JNJ) and set a price target of $176.00.

    Johnson & Johnson (JNJ): A Dividend Aristocrat With Unmatched Stability

    The rating update came after Johnson & Johnson (NYSE:JNJ) reported on September 29 the approval of TREMFYA for “pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six years and older, weighing at least 40 kg”.

    Management reported that the approval was based on the PROTOSTAR study that demonstrated pediatric patients receiving TREMFYA attained high levels of skin clearance vs. placebo at Week 16.

    Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech.

    The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields.

    While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

    Disclosure: None. This article is originally published at Insider Monkey.

    [ad_2]

    Source link

  • These 4 Dividend Stocks Are Money-Printing Machines

    [ad_1]

    • Coca-Cola has paid nearly $100 billion in dividends over the past 15 years.

    • ExxonMobil returned $36 billion in cash to shareholders last year, the fifth-most among S&P 500 members.

    • Johnson & Johnson generated $20 billion in free cash flow last year, easily covering its dividend outlay.

    • 10 stocks we like better than Coca-Cola ›

    Some companies excel at generating cash. They operate mature businesses that produce significantly more profit than they need to support their continued expansion. That gives them lots of money to pay dividends.

    Here are four top money-printing dividend stocks.

    Image source: Getty Images.

    Coca-Cola (NYSE: KO) owns an iconic portfolio of soft drinks, water, teas, and other beverage brands that generate substantial cash. Last year, the company produced $10.8 billion in free cash flow, $8.5 billion of which it paid out in dividends. Over the last 15 years, it has distributed nearly $100 billion in cash dividends to shareholders.

    The company’s durable and growing cash flows have enabled it to steadily increase its dividend payment. Coca-Cola raised it by 5.2% earlier this year, the 63rd straight year it has increased its payout. That puts the beverage giant in the elite group of Dividend Kings, companies with at least 50 years of consecutive annual dividend increases.

    The company expects to produce even more cash in the future. Its long-term target is to organically grow its revenue by 4% to 6% annually, which should drive annual growth in earnings per share in the mid to high single digits. Coca-Cola plans to convert 90% to 95% of its growing earnings into free cash flow, which should support continued dividend increases.

    ExxonMobil (NYSE: XOM) runs a large-scale global energy business that consistently produces significant cash flows. Last year, Exxon generated $55 billion in cash flow from operations, marking its third-best year in a decade, even though oil and gas prices were around their historical averages.

    The company produced $36.2 billion in free cash flow and returned $36 billion to shareholders via dividends ($16.7 billion) and share repurchases ($19.3 billion). Those cash returns led the oil sector and ranked as the fifth-highest among S&P 500 companies.

    The oil giant expects to invest $165 billion into major growth projects and its Permian Basin development program through 2030. These high-return investments should grow its annualized cash flows by $30 billion by 2030, assuming stable oil prices.

    That has it on pace to produce a huge gusher of $165 billion in cumulative surplus cash over the next five years, which should support continued payout increases. With 42 straight years of dividend growth, Exxon has reached a level that only 4% of companies in the S&P 500 have achieved.

    [ad_2]

    Source link

  • All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year

    All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year

    [ad_1]

    The Dow Jones Industrial Average (DJINDICES: ^DJI) has 30 industry-leading components that act as representatives of the U.S. economy. The index’s rich history has made it a go-to destination for investors looking for quality names that can help them generate dividend income.

    Over time, the composition of the Dow has changed to reflect the growing influence of technology on the economy, which has helped the Dow produce impressive gains in recent years. But even stodgy Dow names like Coca-Cola, Home Depot, and McDonald’s have been roaring higher in recent months and helped the index achieve a fresh all-time high on Oct. 11.

    Despite the Dow’s track record, not every component has a high yield or has been a trustworthy dividend stock. Boeing‘s slew of challenges pressured the company to suspend its dividend. Tech stocks like Microsoft, Apple, and Salesforce have yields under 1%, and Amazon doesn’t pay dividends.

    Johnson & Johnson (NYSE: JNJ), Dow (NYSE: DOW), and Chevron (NYSE: CVX) are three of the highest-yielding stocks in the index. Investing $2,500 into each stock produces an average yield of 4.2% and should generate at least $300 in passive income per year. Here’s why all three dividend stocks are worth buying now.

    A chemical plant at dusk.

    Image source: Getty Images.

    J&J has dealt with significant challenges over the last few years

    Johnson & Johnson (J&J) is a Dividend King with 62 consecutive years of dividend increases. The company has long been known as a stodgy passive-income powerhouse. But the last few years have been challenging, as reflected in its languishing stock price.

    J&J was a leader in COVID-19 vaccine developments, which was initially a boon for the company. But rapidly declining demand for the vaccine has been a drag on the company to the point where J&J now reports many of its results as “excluding the impact of the COVID-19 vaccine.”

    Another challenge has been adjusting to the spinoff of J&J’s consumer health business, which occurred in August 2023. Former J&J brands, such as Band-Aid and Tylenol, are now under the new entity Kenvue. The spinoff should help J&J be a faster-growing company by focusing on just two segments — Innovative Medicine and MedTech. However, it does remove some of the safe and stodgy parts of the business that made J&J a rock-solid dividend stock, no matter the economic cycle.

    Finally, J&J has been dealing with lawsuits that allege its talc-based products led to cancer development. J&J restructured and made a subsidiary called Red River Talc LLC, which filed for Chapter 11 bankruptcy on Sept. 20 to handle current and future claims.

    After a messy few years, J&J is finally ready to turn the corner. The business has been putting up solid results and growing at a rate that should support good, if not excellent, dividend raises going forward. J&J generates a ton of free cash flow that easily covers its dividend expense. And with a yield of 3.1%, J&J stands out compared to the S&P 500 dividend yield of just 1.2%.

    Dow is a coiled spring for economic growth

    Not to be confused with the “Dow” in the Dow Jones Industrial Average, Dow makes chemicals used in plastics, seals, foams, gels, adhesives, resins, coatings, and more. The commodity chemical company has three key segments — Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.

    Dow’s business model is capital intensive and vulnerable to ebbs and flows in global demand and supply. Dow has been hit hard by volume declines and lower margins. In the following chart, you can see that revenue and margins surged in 2021 and early 2022 but have fallen considerably since then. Similarly, the stock price has gone practically nowhere since the spinoff.

    DOW ChartDOW Chart

    Dow has blamed macroeconomic factors as a key reason for its weak results. However, low interest rates could greatly benefit many of the company’s end markets. For example, lower mortgage interest rates could boost housing demand, which would help Dow’s polyurethanes and construction chemicals business. Lower interest rates could also boost demand for durable goods.

    Overall, Dow is well positioned to see a sizable uptick in earnings next year. Analyst consensus estimates call for just $2.26 in earnings per share (EPS) in 2024 but $3.55 in 2025 EPS. Although Dow looks expensive based on trailing earnings, it would have a far more reasonable valuation if it delivers on expectations.

    Despite the volatility of Dow’s performance, it has proven to be a reliable income stock spinning off from DowDuPont in 2019. Dow yields 5.2%, making it the second-highest yielding stock in the Dow Jones, behind only Verizon Communications. Dow hasn’t raised its payout since the spinoff, but it has incorporated stock repurchases as part of its capital return program. The company’s goal is to return 65% of earnings to shareholders through buybacks and dividends so it has enough dry powder to fund long-term investments in new production plans, low-carbon efforts, and more.

    Overall, Dow is a good value stock for income investors to consider now.

    A quality energy stock with a high yield

    Like Dow, Chevron can be a highly cyclical business whose results are heavily impacted by commodity prices. But Chevron has a strong balance sheet, a diversified upstream business that doesn’t depend on one production region, a massive refining business, and a track record for raising its dividend no matter what oil prices are doing.

    In fact, Chevron has paid and raised its dividend for 37 consecutive years. Chevron yields 4.3%, which is the third-highest yield in the Dow Jones. The company’s track record for dividend raises, paired with its high yield, makes it arguably the single best passive income play out of the 30 Dow components.

    Investors worried about declining oil prices can take solace in knowing that Chevron has a large margin for error in supporting its dividend. Chevron’s capital expenditures and buybacks are near five-year highs. If oil prices tank, Chevron can simply pause buybacks and pull back on capital expenditures. Chevron didn’t cut its dividend when oil prices crashed in 2020, so it stands to reason that it would take a prolonged downturn for the company even to consider reducing its payout.

    Chevron stands out as a balanced buy for investors looking for a safer way to invest in oil and gas and power their passive income stream.

    Should you invest $1,000 in Johnson & Johnson right now?

    Before you buy stock in Johnson & Johnson, consider this:

    The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

    Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $845,679!*

    Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

    See the 10 stocks »

    *Stock Advisor returns as of October 14, 2024

    John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Daniel Foelber has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Apple, Chevron, Home Depot, Kenvue, Microsoft, and Salesforce. The Motley Fool recommends Johnson & Johnson and Verizon Communications and recommends the following options: long January 2026 $13 calls on Kenvue, long January 2026 $395 calls on Microsoft, and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

    All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year was originally published by The Motley Fool

    [ad_2]

    Source link

  • Nvidia, Google, Microsoft and more head to Las Vegas to tout health-care AI tools

    Nvidia, Google, Microsoft and more head to Las Vegas to tout health-care AI tools

    [ad_1]

    Visitors check out Nvidia’s AI technology at the 2024 Apsara Conference in Hangzhou, China, on September 19, 2024.

    Costfoto | Nurphoto | Getty Images

    Nvidia, Google, Microsoft and dozens of other tech companies are descending on Las Vegas next week to showcase artificial intelligence tools they say will save doctors and nurses valuable time. 

    Sunday marks the official start of a health-care technology conference called HLTH, which is expected to draw more than 12,000 industry leaders this year. CNBC will be on the ground. Based on the speaking agenda and announcements leading up to the conference, AI tools to conquer administrative burdens will be the star of this year’s show. 

    Doctors and nurses are responsible for mountains of documentation as they work to keep up with patient records, interface with insurance companies and comply with regulators. Often, these tasks are painstakingly manual, in part because health data is siloed and stored across multiple vendors and formats. 

    The daunting administrative workload is a major cause of burnout in the industry, and it’s part of the reason a nationwide shortage of 100,000 health-care workers is expected by 2028, according to consulting firm Mercer. Tech companies, eager to carve out a piece of a market that could top $6.8 trillion in spending by the decade’s end, argue that their generative AI tools can help.

    Alex Schiffhauer, group product manager at Google, speaks during the Made By Google event at the company’s Bay View campus in Mountain View, California, Aug. 13, 2024.

    Josh Edelson | AFP | Getty Images

    Google, for instance, said it’s working to expand its health-care customer base by tackling administrative burden with AI.

    On Thursday, the company announced the general availability of Vertex AI Search for Healthcare, which it introduced in a trial capacity during HLTH last year. Vertex AI Search for Healthcare allows developers to build tools to help doctors quickly search for information across disparate medical records, Google said. New features within Google’s Healthcare Data Engine, which helps organizations build the platforms they need to support generative AI, are also now available, the company said.

    Google on Thursday released the results of a survey that said clinicians spend nearly 28 hours a week on administrative tasks. In the survey, 80% of providers said this clerical work takes away from their time with patients, and 91% said they feel positive about using AI to streamline these tasks. 

    Microsoft CEO Satya Nadella speaks at a company event on artificial intelligence technologies in Jakarta, Indonesia, on April 30, 2024.

    Dimas Ardian | Bloomberg | Getty Images

    Similarly, Microsoft on Oct. 11 announced its collection of tools that aim to lessen clinicians’ administrative workload, including medical imaging models, a health-care agent service and an automated documentation solution for nurses, most of which are still in the early stages of development. 

    Microsoft already offers an automated documentation tool for doctors through its subsidiary, Nuance Communications, which it acquired in a $16 billion deal in 2021. The tool, called DAX Copilot, uses AI to transcribe doctors’ visits with patients and turn them into clinical notes and summaries. Ideally, this means doctors don’t have to spend time typing out these notes themselves. 

    Nurses and doctors complete different types of documentation during their shifts, so Microsoft said it’s building a separate tool for nurses that’s best suited to their workflows. 

    AI scribe tools such as DAX Copilot have exploded in popularity this year, and Nuance’s competitors, such as Abridge, which has reportedly raised more than $460 million, and Suki, which has raised $165 million, will also be at the HLTH conference. 

    Dr. Shiv Rao, the founder and CEO of Abridge, told CNBC in March that the rate at which the health-care industry has adopted this new form of clinical documentation feels “historic.” Abridge received a coveted investment from Nvidia’s venture capital arm that same month. 

    Nvidia is also gearing up to address doctor and nurse workloads at HLTH. 

    Kimberly Powell, the company’s vice president of health care, is delivering a keynote Monday that will explain how using generative AI will help health-care professionals “dedicate more time to patient care,” according to the conference’s website.

    Nvidia’s graphics processing units, or GPUs, are used to create and deploy the models that power OpenAI’s ChatGPT and similar applications. As a result, Nvidia has been one of the primary beneficiaries of the AI boom. Nvidia shares are up more than 150% year to date, and the stock tripled last year. 

    The company has been making steady inroads into the health-care sector in recent years, and it offers a range of AI tools across medical devices, drug discovery, genomics and medical imaging. Nvidia also announced expanded partnerships with companies such as Johnson & Johnson and GE HealthCare in March. 

    While the health-care sector has historically been slow to adopt new technology, the buzz around administrative AI tools has been undeniable since ChatGPT exploded onto the scene two years ago. 

    Even so, many health systems are still in the early stages of evaluating tools and vendors, and they’ll be making the rounds on the HLTH exhibition floor. Tech companies will have to prove they have the chops to tackle one of health care’s most complex problems. 

    [ad_2]

    Source link

  • Earnings will drive the stock market in the week ahead. That’s a good thing

    Earnings will drive the stock market in the week ahead. That’s a good thing

    [ad_1]

    A view of the New York Stock Exchange building in the Financial District in New York City on Aug. 5, 2024.

    Charly Triballeau | Afp | Getty Images

    The good times are still rolling on Wall Street. An intensifying earnings season will put that momentum to the test.

    [ad_2]

    Source link

  • Johnson & Johnson (NYSE:JNJ) Shares Sold by HBK Sorce Advisory LLC

    Johnson & Johnson (NYSE:JNJ) Shares Sold by HBK Sorce Advisory LLC

    [ad_1]

    HBK Sorce Advisory LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.5% in the second quarter, HoldingsChannel reports. The firm owned 53,703 shares of the company’s stock after selling 2,517 shares during the period. HBK Sorce Advisory LLC’s holdings in Johnson & Johnson were worth $7,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

    Several other hedge funds also recently added to or reduced their stakes in the business. Gilbert & Cook Inc. raised its stake in Johnson & Johnson by 3.3% in the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after purchasing an additional 288 shares during the last quarter. 9258 Wealth Management LLC boosted its position in Johnson & Johnson by 2.1% during the fourth quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock worth $3,454,000 after acquiring an additional 443 shares during the last quarter. Gryphon Financial Partners LLC raised its holdings in Johnson & Johnson by 66.3% in the 4th quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company’s stock valued at $2,244,000 after acquiring an additional 5,680 shares during the last quarter. Wade G W & Inc. lifted its stake in Johnson & Johnson by 0.6% in the 4th quarter. Wade G W & Inc. now owns 217,026 shares of the company’s stock worth $34,017,000 after purchasing an additional 1,332 shares in the last quarter. Finally, Inceptionr LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $404,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

    Insider Transactions at Johnson & Johnson

    In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

    Analyst Ratings Changes

    A number of equities analysts recently commented on JNJ shares. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 9th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.21.

    Read Our Latest Stock Analysis on JNJ

    Johnson & Johnson Stock Up 0.5 %

    Shares of JNJ opened at $165.52 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a market capitalization of $398.45 billion, a PE ratio of 10.32, a P/E/G ratio of 2.71 and a beta of 0.53. The company’s 50-day simple moving average is $159.55 and its 200-day simple moving average is $153.99. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the company posted $2.80 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

    Johnson & Johnson Announces Dividend

    The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

    Johnson & Johnson Company Profile

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

    Featured Stories

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Johnson & Johnson (NYSE:JNJ) is Tweedy Browne Co LLC’s 3rd Largest Position

    Johnson & Johnson (NYSE:JNJ) is Tweedy Browne Co LLC’s 3rd Largest Position

    [ad_1]

    Tweedy Browne Co LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,133,725 shares of the company’s stock after selling 1,393 shares during the quarter. Johnson & Johnson makes up approximately 8.4% of Tweedy Browne Co LLC’s portfolio, making the stock its 3rd largest holding. Tweedy Browne Co LLC’s holdings in Johnson & Johnson were worth $179,344,000 at the end of the most recent reporting period.

    Several other large investors also recently bought and sold shares of JNJ. Pathway Financial Advisors LLC raised its position in shares of Johnson & Johnson by 4.3% during the 4th quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock valued at $852,000 after buying an additional 226 shares during the period. Daiwa Securities Group Inc. lifted its stake in shares of Johnson & Johnson by 5.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock valued at $46,685,000 after purchasing an additional 15,490 shares during the last quarter. OneAscent Financial Services LLC grew its holdings in shares of Johnson & Johnson by 82.8% during the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock worth $1,542,000 after purchasing an additional 4,457 shares during the period. Drive Wealth Management LLC increased its position in shares of Johnson & Johnson by 4.5% during the 1st quarter. Drive Wealth Management LLC now owns 9,625 shares of the company’s stock worth $1,523,000 after purchasing an additional 414 shares during the last quarter. Finally, Vestmark Advisory Solutions Inc. lifted its position in Johnson & Johnson by 12.7% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock valued at $3,070,000 after buying an additional 2,201 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

    Johnson & Johnson Stock Up 0.1 %

    Shares of NYSE:JNJ opened at $149.88 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The firm has a 50 day simple moving average of $147.94 and a 200-day simple moving average of $153.50. The company has a market capitalization of $360.71 billion, a PE ratio of 9.34, a P/E/G ratio of 2.49 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the prior year, the firm posted $2.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.61 EPS for the current fiscal year.

    Johnson & Johnson Increases Dividend

    The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.31%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

    Analyst Upgrades and Downgrades

    JNJ has been the topic of several recent analyst reports. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. The Goldman Sachs Group began coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target for the company. Bank of America decreased their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $174.07.

    Read Our Latest Stock Report on JNJ

    Johnson & Johnson Company Profile

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

    Featured Stories

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations

    Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations

    [ad_1]

    Jonathan Raa | Nurphoto | Getty Images

    A federal judge in New Jersey on Monday rejected Johnson & Johnson‘s and Bristol Myers Squibb‘s legal challenges to the Biden administration’s Medicare drug-price negotiations, ruling that the program is constitutional. 

    The decision is another win for the White House in a bitter legal fight with several drugmakers over the price talks. The ruling also weakens the pharmaceutical industry’s strategy of seeking split decisions in lower courts scattered across the U.S., which could escalate the issue to the Supreme Court. 

    Medicare drug-price negotiations are a key policy under President Joe Biden’s Inflation Reduction Act that aims to make costly medications more affordable for seniors. In doing so, it could take a bite out of drugmakers’ profits. Final negotiated prices for the first round of drugs subject to the talks, which includes one each from J&J and Bristol Myers, will go into effect in 2026. 

    J&J and Bristol Myers Squibb did not immediately respond to requests for comment on the ruling. 

    In separate lawsuits, the drugmakers argued that the negotiations are an unconstitutional confiscation of their drugs by the government and a violation of their right to freedom of speech. They also argued that the talks are an unconstitutional condition to participate in the Medicaid and Medicare programs.

    But Judge Zahid Quraishi of the District of New Jersey wrote in a 26-page opinion that participation in the price talks and Medicare and Medicaid markets is voluntary.

    The negotiations don’t require drugmakers to “set aside, keep or otherwise reserve any of their drugs” for the use of the government or Medicare beneficiaries, he wrote. Quraishi added the talks don’t force manufacturers to physically transmit or transport drugs at a new negotiated price.

    “Selling to Medicare may be less profitable than it was before the institution of the Program, but that does not make [J&J and Bristol Myers Squibb’s] decision to participate any less voluntary,” Quraishi wrote. “For the reasons provided, the Court concludes that the Program does not result in a physical taking nor direct appropriation” of medications from the two drugmakers. 

    J&J, Bristol Myers Squibb, Novo Nordisk and Novartis presented their oral arguments before Quraishi during the same hearing in March.

    That same month, a federal judge in Delaware rejected AstraZeneca’s separate lawsuit challenging the negotiations. In Texas, a third federal judge tossed a separate lawsuit in February.

    A federal judge in Ohio also issued a ruling in September denying a preliminary injunction sought by the Chamber of Commerce, one of the largest lobbying groups in the country, which aimed to block the price talks before Oct. 1.

    Don’t miss these exclusives from CNBC PRO

    [ad_2]

    Source link

  • Nvidia and Johnson & Johnson to develop new AI applications for surgery

    Nvidia and Johnson & Johnson to develop new AI applications for surgery

    [ad_1]

    The New York Stock Exchange welcomes Johnson & Johnson.

    NYSE

    Johnson & Johnson on Monday announced it is working with Nvidia to develop and scale new artificial intelligence applications for surgery. 

    J&J’s MedTech unit and Nvidia plan to integrate AI within devices and platforms from pre-op to post-op to help ensure that surgeons have access to all the information they need, Nvidia’s vice president of health care Kimberly Powell said. For instance, the companies are using AI to analyze surgical video and automate the time-consuming documentation required after a procedure. 

    “There’s an ability to use all the sources of data inside an operating room, whether it’s your voice, or whether it’s the video coming from a camera inside the body, or elsewhere, to take advantage of the generative AI moment that we’re in,” Powell told CNBC in an interview. 

    The MedTech unit at J&J creates tools and solutions for conditions such as heart failure, kidney disease and stroke, and its technology is used in more than 75 million procedures each year, the company told CNBC. Powell said Nvidia has worked in medical devices and imaging for more than a decade. 

    Shan Jegatheeswaran, vice president and global head of digital at J&J MedTech, said just one minute of surgical video is equivalent to roughly 25 CT scans, so having the compute power and infrastructure to annotate and share those videos widely will be powerful for surgeons.

    In the short term, he said de-identifying and enhancing the video can help educate and train surgeons. In the long term, analytics can be layered on top of video to provide real-time decision support. More accessible surgical video means residents will not have to solely depend on the insight and availability of the more experienced physicians at their institutions. 

    “Think about athletes. They look at game tape, and they get better over time as they look at themselves,” Jegatheeswaran told CNBC in an interview. “That’s sort of the starting point. That’s the holy grail in the short term.”

    Powell said the collaboration is in the “early innings,” and many applications will take time to fine-tune and implement safely. However, she said nondiagnostic use cases such as automating paperwork will help save surgeons time and make a difference “right out of the gate.”

    “I think all of us as patients should get really excited about the fact that this kind of technology is going to be able to enter in and be within reach of all the clinicians and all the hardworking nurses and all the health-care staff,” Powell said. “They’re going to have the very best tools and information at their disposal.”

    Don’t miss these stories from CNBC PRO:

    [ad_2]

    Source link

  • Sun Life and Johnson & Johnson ink deal to promote healthier lives for Filipinos

    Sun Life and Johnson & Johnson ink deal to promote healthier lives for Filipinos

    [ad_1]

    Sun Life Financial Inc., Sun Life of Canada (Philippines) Inc., and Johnson & Johnson Philippines, Inc. (J&J) reaffirm their commitment to helping Filipinos achieve a brighter life as they enter a collaboration that promotes financial literacy and health and wellness. 

    The two stalwarts in their respective fields have agreed to promote financial medical literacy among their target audience through a series of talks and forums. This kicked off with webinars on mental wellness and prostate cancer awareness for Sun Life employees, followed by a two-part financial planning session for J&J employees.  

    The program continues onwards with the creation of appropriate awareness tools as well as products and services that will address the financial, medical, and insurance needs of Filipinos. 

    “Health is wealth, and as cliché as it may sound, there is nothing truer than this because living a healthier  life allows one to pursue a brighter future,” says Alex Narciso, president of Sun Life of Canada (Philippines),  Inc. “By joining forces with Johnson & Johnson, we earnestly look forward to ushering more Filipinos towards  a future that’s brighter, healthier, and more financially secure.” 

    “Our entry in this valuable collaboration transcends our business and objectives, and it’s truly great and wonderful that we are working together for this shared mission as we deliver life-changing values that aid in promoting a healthier life among Filipinos, starting with our employees,” says Anna Cristina Blaza,  commercial leader of Johnson & Johnson Philippines. 

    Present during the occasion were Sun Life’s top executives namely: Alex Narciso, president; Al Quitangon,  chief distribution officer; Deo Orpilla, chief distribution & business development officer; Lirio Torres, head of health & accident; and May Oruga, health affinity partner. Coming from J&J are: Noel Borlongan, head of government affairs; Anna Cristina Blaza, commercial leader; Dr. Lorenz Angeles, medical affairs; Johanna  Santiago, market access; and Dorothy Regmalos, market access admin assistant. The event was hosted by  Francesca Tolentino, Sun Life’s lead of Affinity.  

    Sun Life has always been at the forefront of helping Filipinos live healthier lives, from offering a wide array of health protection plans to mounting activities that promote physical activity, such as Sun Life Cycle PH and the Sun Life 5150 Triathlon.

    [ad_2]

    Gadgets Magazine 17

    Source link

  • Blood Donations from COVID-19 Vaccine Recipients Are Safe, Contrary to Online Claims

    Blood Donations from COVID-19 Vaccine Recipients Are Safe, Contrary to Online Claims

    [ad_1]

    SciCheck Digest

    People vaccinated with an authorized or approved COVID-19 vaccine can donate blood immediately after receiving a shot if they’re feeling well. Social media posts distort a question from the American Red Cross to baselessly claim the vaccines are unsafe.

    Full Story

    Nearly two years after related claims about COVID-19 vaccination and blood donation first surfaced, posts on social media are now pointing to a blood donation screening question to falsely suggest the vaccines are unsafe.  

    Multiple Feb. 20 posts shared a screenshot of a question included in RapidPass, a pre-donation tool the American Red Cross uses to streamline the blood donation process. The question asks if a person has “EVER had a Coronavirus (COVID-19) vaccine.” Those who answer “yes” are told to call the Red Cross “to determine if this will affect” their eligibility to donate. The posts incorrectly imply the question is new and could mean the vaccines are not safe.

    [ad_2]

    FactCheck.org

    Source link

  • Johnson & Johnson (NYSE:JNJ) Shares Sold by Burke & Herbert Bank & Trust Co.

    Johnson & Johnson (NYSE:JNJ) Shares Sold by Burke & Herbert Bank & Trust Co.

    [ad_1]

    Burke & Herbert Bank & Trust Co. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 18.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 22,909 shares of the company’s stock after selling 5,164 shares during the quarter. Johnson & Johnson accounts for approximately 2.9% of Burke & Herbert Bank & Trust Co.’s investment portfolio, making the stock its 6th biggest holding. Burke & Herbert Bank & Trust Co.’s holdings in Johnson & Johnson were worth $3,568,000 at the end of the most recent quarter.

    Several other institutional investors and hedge funds have also made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 1.4% during the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock worth $31,231,193,000 after buying an additional 2,688,798 shares during the period. State Street Corp lifted its stake in shares of Johnson & Johnson by 1.1% during the second quarter. State Street Corp now owns 141,833,756 shares of the company’s stock worth $23,476,323,000 after buying an additional 1,568,633 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Johnson & Johnson by 2.0% during the second quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock worth $8,203,608,000 after purchasing an additional 990,298 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

    Analyst Ratings Changes

    Several brokerages recently issued reports on JNJ. Cantor Fitzgerald reissued an “overweight” rating on shares of Johnson & Johnson in a report on Monday, December 18th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Royal Bank of Canada reissued an “outperform” rating and set a $178.00 target price on shares of Johnson & Johnson in a report on Friday, December 1st. Finally, Raymond James cut their price objective on shares of Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating for the company in a report on Wednesday, October 18th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $168.75.

    Read Our Latest Stock Report on JNJ

    Johnson & Johnson Stock Up 0.2 %

    Shares of NYSE JNJ opened at $156.61 on Friday. The company’s 50-day simple moving average is $152.48 and its 200-day simple moving average is $159.60. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $180.93. The firm has a market cap of $377.00 billion, a price-to-earnings ratio of 11.63, a price-to-earnings-growth ratio of 3.20 and a beta of 0.57. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The business had revenue of $21.35 billion for the quarter, compared to analyst estimates of $21 billion. Equities analysts predict that Johnson & Johnson will post 9.96 EPS for the current fiscal year.

    Johnson & Johnson Announces Dividend

    The business also recently announced a quarterly dividend, which was paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st were given a $1.19 dividend. The ex-dividend date of this dividend was Monday, November 20th. This represents a $4.76 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is 35.34%.

    Johnson & Johnson Profile

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

    Further Reading

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Johnson & Johnson (NYSE:JNJ) Shares Acquired by Kingdom Financial Group LLC.

    Johnson & Johnson (NYSE:JNJ) Shares Acquired by Kingdom Financial Group LLC.

    [ad_1]

    Kingdom Financial Group LLC. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 258.0% during the third quarter, Holdings Channel reports. The fund owned 9,268 shares of the company’s stock after purchasing an additional 6,679 shares during the quarter. Johnson & Johnson comprises 1.4% of Kingdom Financial Group LLC.’s portfolio, making the stock its 17th biggest holding. Kingdom Financial Group LLC.’s holdings in Johnson & Johnson were worth $1,443,000 as of its most recent SEC filing.

    A number of other large investors have also made changes to their positions in the stock. Hibernia Wealth Partners LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $27,000. Atlantic Private Wealth LLC acquired a new stake in Johnson & Johnson in the 1st quarter worth about $32,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $37,000. VitalStone Financial LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth about $48,000. Finally, Horizons Wealth Management lifted its stake in shares of Johnson & Johnson by 1,730.0% in the 2nd quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after purchasing an additional 346 shares in the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

    Johnson & Johnson Trading Up 0.1 %

    NYSE:JNJ opened at $156.35 on Thursday. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $180.93. The firm has a market capitalization of $376.38 billion, a P/E ratio of 11.61, a P/E/G ratio of 3.18 and a beta of 0.57. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96. The business has a 50 day simple moving average of $152.40 and a 200 day simple moving average of $159.62.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. The business had revenue of $21.35 billion during the quarter, compared to analyst estimates of $21 billion. Equities research analysts predict that Johnson & Johnson will post 9.96 EPS for the current year.

    Johnson & Johnson Dividend Announcement

    The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st were given a dividend of $1.19 per share. The ex-dividend date was Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is currently 35.34%.

    Analysts Set New Price Targets

    Several research firms have recently weighed in on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Monday, December 18th. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Raymond James dropped their target price on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, October 18th. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $167.00 to $180.00 in a report on Friday, December 1st. Finally, HSBC initiated coverage on Johnson & Johnson in a report on Wednesday, September 6th. They set a “hold” rating and a $175.00 price objective on the stock. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $168.75.

    Get Our Latest Research Report on Johnson & Johnson

    About Johnson & Johnson

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

    Featured Articles

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Johnson & Johnson (NYSE:JNJ) Shares Sold by M&R Capital Management Inc.

    Johnson & Johnson (NYSE:JNJ) Shares Sold by M&R Capital Management Inc.

    [ad_1]

    M&R Capital Management Inc. reduced its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,635 shares of the company’s stock after selling 811 shares during the quarter. Johnson & Johnson makes up about 1.1% of M&R Capital Management Inc.’s investment portfolio, making the stock its 23rd biggest holding. M&R Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,837,000 at the end of the most recent reporting period.

    Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC grew its stake in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $4,609,399,000. Capital International Investors boosted its holdings in shares of Johnson & Johnson by 62.7% during the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after acquiring an additional 10,724,110 shares during the period. Journey Strategic Wealth LLC boosted its holdings in shares of Johnson & Johnson by 161,420.2% during the second quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock valued at $1,204,404,000 after acquiring an additional 7,271,978 shares during the period. Finally, Providence Capital Advisors LLC boosted its holdings in shares of Johnson & Johnson by 141,974.0% during the first quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock valued at $30,651,000 after acquiring an additional 4,747,612 shares during the period. 68.40% of the stock is owned by institutional investors.

    Wall Street Analyst Weigh In

    JNJ has been the subject of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $178.00 price target on shares of Johnson & Johnson in a report on Friday, December 1st. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating for the company in a report on Wednesday, October 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 26th. Finally, Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $168.75.

    Read Our Latest Stock Analysis on Johnson & Johnson

    Johnson & Johnson Price Performance

    JNJ stock opened at $156.46 on Wednesday. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a one year low of $144.95 and a one year high of $180.93. The firm has a market capitalization of $376.64 billion, a PE ratio of 11.62, a P/E/G ratio of 3.17 and a beta of 0.57. The firm has a 50-day moving average of $152.51 and a two-hundred day moving average of $159.79.

    Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The company had revenue of $21.35 billion during the quarter, compared to analyst estimates of $21 billion. On average, analysts forecast that Johnson & Johnson will post 9.97 earnings per share for the current year.

    Johnson & Johnson Announces Dividend

    The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st were issued a $1.19 dividend. The ex-dividend date of this dividend was Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is 35.34%.

    Johnson & Johnson Profile

    (Free Report)

    Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

    Featured Stories

    Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

    Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

    Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Here are Wednesday's biggest analyst calls: Tesla, Walmart, Qualcomm, Deere, Robinhood, Shopify & more

    Here are Wednesday's biggest analyst calls: Tesla, Walmart, Qualcomm, Deere, Robinhood, Shopify & more

    [ad_1]

    [ad_2]

    Source link

  • Warren Buffett’s Berkshire trimming holdings, keeping new stock secret

    Warren Buffett’s Berkshire trimming holdings, keeping new stock secret

    [ad_1]

    [ad_2]

    Source link